Lapatinib for breast cancer: a review of the current literature (Q37810946)

23 August 2017

Lapatinib for breast cancer: a review of the current literature (English)

1 reference

23 August 2017

Robyn J MacFarlane

1

1 reference

PubMed ID

21091041

23 August 2017

Karen A Gelmon

series ordinal

2

1 reference

PubMed ID

21091041

23 August 2017

language of work or name

English

0 references

publication date

20 November 2010

1 reference

Expert Opinion on Drug Safety

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

1

1 reference

23 August 2017

109-121

1 reference

23 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Emerging drugs to replace current leaders in first-line therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Resistance to Trastuzumab in Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Epidermal growth factor receptors: critical mediators of multiple receptor pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

FDA drug approval summary: erlotinib (Tarceva) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Systemic therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Breast cancer metastasis to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Brain metastases: the HER2 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Survival after brain metastases from breast cancer in the trastuzumab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.533168

10.1517/14740338.2011.533168

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21091041